LETTERS TO THE EDITOR

fibrillation

JANUARY 2017

informative.

Anticoagulation for atrial

TO THE EDITOR: As a geriatric medicine fellow, I

eagerly read Hagerty and Rich's review "Fall

risk and anticoagulation for atrial fibrillation

in the elderly: A delicate balance"1 and Suh's

editorial, "Whether to anticoagulate: Toward

a more reasoned approach"² in the January 2017 issue. Both pieces were helpful and

I appreciate that Dr. Suh encourages

shared decision-making between physicians

and patients that balances patient preferenc-

es and risk stratification to inform whether

to anticoagulate. He states, "Unfortunately,

there is no similar screening tool to predict

of the risk spectrum... The patient's life expec-

tancy and personal preferences are important

Dr. Mark Eckman's Atrial Fibrillation De-

independent factors that affect the decision

cision Support Tool (AFDST) incorporates

patients' CHA2DS2-VASc and HAS-BLED

of whether to anticoagulate or not."

bleeding risk from anticoagulation with greater precision in the middle to lower part

tool helps guide physicians and patients to make shared decisions about anticoagulation.^{3–5} The AFDST informs clinicians if a patient is undertreated or being treated unnecessarily. Eckman and his colleagues have demonstrated the AFDST's effective application in clinical practice, including for older adults. I invite readers to learn more about Eckman's work!

> ELISE HENNING, MD, MED Geriatric Medicine Fellow University of Cincinnati/Christ Hospital

REFERENCES

- Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: a delicate balance. Cleve Clin J Med 2017; 84:35–40.
- Suh TT. Whether to anticoagulate: toward a more reasoned approach. Cleve Clin J Med 2017; 84:41–42.
- 3. Eckman MH, Lip GYH, Wise RE, et al. Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation. Am Heart J 2016; 176:17–27.

4. Eckman MH, Wise RE, Speer B, et al. Integrating realtime clinical information to provide estimates of net clinical benefit antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2014; 7:680–686.

 Eckman MH, Lip TYH, Wise RE, et al. Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc 2016; 64:1054–1060.

doi:10.3949/ccjm.84c.09001

IN REPLY: I appreciate Dr. Henning's letter in response to my editorial.¹ Indeed, Dr. Eckman's Atrial Fibrillation Decision Support Tool (AFDST) is useful for determining quality-adjusted life expectancy on or off anticoagulation, and could possibly help with shared decision-making in regard to anticoagulation.^{2–4}

However, the AFDST does not incorporate personal preferences regarding anticoagulant or medication use in general. Many older adults are on too many medications (ie, polypharmacy) and wish to reduce their overall pill count.

A number of potential barriers to shared decision-making regarding medication use have been identified, including poor physician communication skills, the growing number of available medications, multiple prescribers for the same patient, lack of trust in the prescribing physician, and patients feeling that their preferences are not valued or important.⁵ Until communication and acceptance between prescribers and patients regarding possible medication choices improves, shared decision-making for medication use in general and anticoagulant use in particular will be an unfulfilled ideal.

THEODORE T. SUH, MD, PhD, MHS, AGSF University of Michigan Geriatric Center Ann Arbor

REFERENCES

- 1. Suh TT. Whether to anticoagulate: toward a more reasoned approach. Cleve Clin J Med 2017; 84:41–42.
- Eckman MH, Lip GYH, Wise RE, et al. Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation. Am Heart J 2016; 176:17–27.
- Eckman MH, Wise RE, Speer B, et al. Integrating realtime clinical information to provide estimates of net clinical benefit antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2014; 7:680–686.

- Eckman MH, Lip TYH, Wise RE, et al. Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc 2016; 64:1054–1060.
- Belcher VN, Fried TR, Agostini JV, Tinetti ME. Views of older adults on patient participation in medication-related decision making. J Gen Intern Med 2006; 21:298–303.

doi:10.3949/ccjm.84c.09002

Cardiac mass: Tumor or thrombus?

JULY 2017

TO THE EDITOR: We read with great interest the article by Patnaik et al¹ about a patient who had a cardiac metastasis of ovarian cancer, and we would like to raise a few points.

It is important to clarify that metastatic cardiac tumors are not necessary malignant. Intravenous leiomyomatosis is a benign small-muscle tumor that can spread to the heart, causing various cardiac symptoms.² Even with extensive disease, patients with intravenous leiomyomatosis may remain asymptomatic until cardiac involvement occurs. The most common cardiac symptoms are dyspnea, syncope, and lower-extremity edema.

Cardiac involvement in intravenous leiomyomatosis may occur via direct invasion or hematogenous or lymphatic spread of the tumor. In leiomyoma and leiomyosarcoma, cardiac invasion usually occurs via direct spread through the inferior vena cava into the right atrium and ventricle. Thus, cardiac involvement with these tumors (except for nephroma) was reported to exclusively involve the right side of the heart.

In 2014, we reported a unique case of intravenous leiomyomatosis that extended from the right side into the left side of the heart and the aorta via an atrial septal defect.² Intracardiac extension of intravenous leiomyomatosis may result in pulmonary embolism, systemic embolization if involving the left side, and, rarely, sudden death.²

In patients with malignancy, differentiating between thrombosis and tumor is critical. These patients have a hypercoagulable state and a fourfold increase in thrombosis risk, and chemotherapy increases this risk even more.³ Although tissue pathology examination is important for differentiating thrombosis from tumor, visualization of the direct extension of the mass from the primary source into the heart through the inferior vena cava by ultrasonography, computed tomography, or magnetic resonance imaging may help in making this distinction.²

> MAHMOUD ABDELGHANY, MD Department of Medicine Division of Cardiology State University of New York Upstate Medical University Syracuse, NY

> MOUSTAFA ELSHESHTAWY, MD Department of Medicine Division of Cardiology Maimonides Medical Center Brooklyn, NY

HANI KOZMAN, MD Department of Medicine Division of Cardiology State University of New York Upstate Medical University Syracuse, NY

REFERENCES

- Patnaik S, Shah M, Sharma S, Ram P, Rammohan HS, Rubin A. A large mass in the right ventricle: tumor or thrombus? Cleve Clin J Med 2017; 84:517–519.
- Abdelghany M, Sodagam A, Patel P, Goldblatt C, Patel R. Intracardiac atypical leiomyoma involving all four cardiac chambers and the aorta. Rev Cardiovasc Med 2014; 15:271–275.
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902–4907.

doi:10.3949/ccjm.84c.09003